Trial report in European heart journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
21 authors.
Miguel A Martínez-GonzálezInstituto de Salud Carlos III, Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBERObn), Madrid, Spain.ORCID 0000-0002-3917-9808
Maira Bes-RastrolloInstituto de Salud Carlos III, Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBERObn), Madrid, Spain.ORCID 0000-0002-9139-4206
Carmen Sayon-OreaInstituto de Salud Carlos III, Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBERObn), Madrid, Spain.ORCID 0000-0002-4137-3263
Miguel Ruiz-CanelaInstituto de Salud Carlos III, Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBERObn), Madrid, Spain.ORCID 0000-0002-7684-2787
Juan TimiraosStroke Unit, Neurology Department, Integrated Health Organization Araba, Vitoria-Gasteiz, Spain.ORCID 0000-0002-9577-648X
Estefanía ToledoInstituto de Salud Carlos III, Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBERObn), Madrid, Spain.ORCID 0000-0002-6263-4434
José V SorlíInstituto de Salud Carlos III, Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBERObn), Madrid, Spain.ORCID 0000-0002-0130-2006
Jordi Salas-SalvadoInstituto de Salud Carlos III, Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBERObn), Madrid, Spain.ORCID 0000-0003-2700-7459
Enrique Gómez-GraciaDepartment of Preventive Medicine, Instituto de Investigación Biomédica de Málaga (IBIMA), University of Malaga, Málaga, Spain.ORCID 0000-0002-1281-5798
Miquel FiolPlatform for Clinical Trials, Instituto de Investigación Sanitaria Illes Balears (IdISBa), Hospital Universitario Son Espases, Palma de Mallorca, Spain.ORCID 0000-0002-5370-1391
Helmut ShröederStroke Unit, Department of Neurology, Neurovascular Research Group, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain.ORCID 0000-0003-2231-5081
José LapetraInstituto de Salud Carlos III, Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBERObn), Madrid, Spain.ORCID 0000-0002-3873-5737
Luis Serra-MajemInstituto de Salud Carlos III, Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBERObn), Madrid, Spain.ORCID 0000-0002-9658-9061
Xavier PintóInstituto de Salud Carlos III, Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBERObn), Madrid, Spain.ORCID 0000-0002-2216-2444
María Barbería-LatasaInstituto de Salud Carlos III, Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBERObn), Madrid, Spain.ORCID 0000-0001-5617-4729
Emilio RosAugust Pi i Sunyer Biomedical Research Institute (IDIBAPS), Hospital Clinic, University of Barcelona, Barcelona, Spain.ORCID 0000-0002-2573-1294
Nancy BabioInstituto de Salud Carlos III, Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBERObn), Madrid, Spain.ORCID 0000-0003-3527-5277
Carolina OrtegaInstituto de Salud Carlos III, Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBERObn), Madrid, Spain.ORCID 0000-0003-2560-1040
Rafael de la TorreInstituto de Salud Carlos III, Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBERObn), Madrid, Spain.ORCID 0000-0002-6765-1866
Rosa M Lamuela-RaventosInstituto de Salud Carlos III, Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBERObn), Madrid, Spain.ORCID 0000-0002-1287-4560
Ramón EstruchInstituto de Salud Carlos III, Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBERObn), Madrid, Spain.ORCID 0000-0003-1260-4445
Funding
CIBEROBNComisión Interministerial de Ciencia y Tecnología PID2020-114022RB-I00European Research Grant #101097681FIVIN FB 600390Generalitat de Catalunya 2017SGR 196Generalitat de Catalunya (GC) 2017SGR 196Interprofesional del vino de España-OIVE CEX2021-001234-MInterprofesional del vino de España-OIVE FB 600390Ministerio de Ciencia e InnovaciónMinisterio de Ciencia e Innovación (MICIN)National Institutes of Health (NIH) 2R01HL118264-09National Institutes of Health (NIH) 5R01HL118264-08NIH HHS 2R01HL118264-09NIH HHS 5R01HL118264-08
6 · The paper itself
Abstract
BACKGROUND AND
aimsThe benefits of the Mediterranean diet (MedDiet) are well established. However, one component, wine, remains controversial. This study assessed the association between MedDiet (with or without wine consumption) and major cardiovascular disease (CVD) or all-cause mortality.
methodsThe PREDIMED trial included 7447 high-risk participants. Adherence to MedDiet was measured using a validated 14-item questionnaire, including one item on wine (cut-off: seven glasses/week). The CVD events were recorded over a 4.8-year follow-up, while all-cause mortality was tracked for 17 years. A younger Spanish cohort (the SUN project), including 23,133 participants followed up for 22 years, was also evaluated.
resultsIn PREDIMED, compared with poor compliers with MedDiet (excluding wine), good compliers (excluding wine), had a multivariable-adjusted hazard ratio (HR) of 0.84 [95% confidence interval (CI) 0.61-1.15] for CVD. For good compliers with MedDiet (including wine), the HR for CVD was 0.55 (95% CI 0.36-0.83). For all-cause mortality, MedDiet compliers (excluding wine) had HR of 0.77 (95% CI 0.68-0.87), which was 0.67 (95% CI 0.57-0.78) for MedDiet compliers (including wine). In exploratory dose-response analyses, reduced risk for death was not present in PREDIMED participants who drank three or more glasses of wine/day. Additionally, analyses least vulnerable to threats of abstainer bias were not significant and neither were multiplicative interaction terms for the wine item in the questionnaire. In the SUN cohort, no significant associations were observed between MedDiet compliance, wine, and CVD. However, for all-cause mortality, the HR was 0.94 (95% CI 0.71-1.26) for MedDiet compliers (excluding wine) and 0.54 (95% CI 0.28-1.04) for MedDiet compliers (including wine). When pooling both cohorts, wine consumption within the MedDiet was associated with lower all-cause mortality (P = .01).
conclusionsIn PREDIMED, moderate wine consumption, as part of the MedDiet, appeared to be associated with lower mortality and CVD risk. Some non-significant associations and interactions advise caution in interpretation of these findings.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Wine consumption, Mediterranean diet, and cardiovascular risk in two Spanish cohorts. · full record | Socratic